ProKidney Corp. - Class A

The momentum for this stock is not very good. ProKidney Corp. - Class A is not a good value stock. ProKidney Corp. - Class A is not a good growth stock. ProKidney Corp. - Class A is not very popular among insiders. Tradey thinks it is not wise to invest in ProKidney Corp. - Class A.

News

ProKidney (NASDAQ:PROK) Coverage Initiated at Guggenheim

Ticker Report Equities researchers at Guggenheim began coverage on shares of ProKidney (NASDAQ:PROK - Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The firm set a "buy" rating and...\n more…

ProKidney initiated with bullish view at Guggenheim, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ProKidney (NASDAQ:PROK) Shares Gap Down Following Analyst Downgrade

Ticker Report ProKidney Corp. (NASDAQ:PROK - Get Free Report) shares gapped down prior to trading on Wednesday after Bank of America lowered their price target on the stock from $4.00 to $3.00. The stock had...\n more…

ProKidney (NASDAQ:PROK) Price Target Lowered to $3.00 at Bank of America

Ticker Report ProKidney (NASDAQ:PROK - Free Report) had its price objective lowered by Bank of America from $4.00 to $3.00 in a research report report published on Wednesday, Benzinga reports. The brokerage...\n more…

ProKidney revises Phase 3 program for lead asset

Seeking Alpha - Healthcare ProKidney revises Phase 3 program for lead asset...\n more…

ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval

FierceBiotech.com - Biotech ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval\njwaldron\nTue, 09/03/2024 - 08:35...\n more…